JOURNAL DE LA VALLEEBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL DE LA VALLEE
Company Title:
Company Description:
Keywords to Search:
Company Address:	94 Rue DE LA Gare #104,ST-SAUVEUR-DES-MONTS,QC,Canada
ZIP Code: Postal Code:	J0R1R6
Telephone Number:	4502274646
Fax Number:	4502278144
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	271101
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	10 to 19
Sales Amount:	$1 to 2.5 million
Credit History: Credit Report:	Excellent
Contact Person:	Gilles Menard
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
KANUK COMPTOIR
KANGUK CARIBOU OUTF INC
KAFY

Next company profile:
JOLICOEUR, PAUL
JEAN COUTU
JAY SET

Company News:

New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Tirzepatide and semaglutide are highly effective medications for obesity management The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di
The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early . . .
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management Additional data on the efficacy and
Recently Published | The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
Coadministered Cagrilintide and Semaglutide in Adults with Overweight . . .
Semaglutide at a dose of 2 4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2 4 mg has shown promising results in early-phase trials; the efficacy of the
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
Zimislecel is an allogeneic stem cell–derived islet-cell therapy Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 . . .
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with
First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
Medical Education | NEJM
The Journal announces a series focused on new, neglected, and insidious disruptions in clinical care environments affecting patient care and education The series aims to stimulate new ways of